Saturday Rounds

Evidence before optionality — a first-line label expansion backed by an 80% risk reduction led the week, large pharma wrote roughly $2.3 billion of upfront checks for early-stage modalities, and two programs that could…

The week’s most important signal was not a new platform claim but five-year, maintenance-free disease control after a single cilta-cel infusion in early-line relapsed or refractory multiple myeloma — and the broader pattern held…

Two rare-disease approvals landed ahead of their own clocks, the FDA launched a pilot explicitly designed to compress first-in-human timelines, and a $350 million IPO priced and opened without a pop — a week…

Four approvals, a first-ever in-vivo CRISPR filing accepted with Priority Review, two high-profile pivotal misses, and roughly $1.6 billion of confirmed private financing — a week where mechanism mattered less than manufacturing, endpoint choice…

Six approvals, a pivotal cardiovascular-outcomes miss, two paused autoimmune cell-therapy programs, and roughly $6.9 billion of headline dealmaking — this week’s signals only counted once verified against a primary source. Weekly Biotech Signal Review…

Biotech had an approval week that tested whether comparative human evidence still beats platform storytelling. Broad active-state RAS inhibition crossed from thesis to approved medicine when the FDA cleared Rasonque after a 500-patient randomized…

Biotech had an approval week. Ultragenyx’s first-ever gene therapy for glycogen storage disease type Ia, Regeneron’s second-ever disease-modifying therapy for fibrodysplasia ossificans progressiva, and Amylyx’s blowout Phase 3 win in post-bariatric hypoglycemia landed within…

Biotech’s week traded distress for discipline: Sangamo’s bankruptcy auction let PTC Therapeutics pick up a near-approval Fabry gene therapy for a fraction of its original value, Bristol Myers Squibb banked the first-ever approval of…

Weekly Biotech Signal Review — Week of July 26-31, 2026.